Intervention

Petrelintide

ClinicalTrials.gov intervention label

Clinical trials7
Recruiting3
Common conditions6
Lead sponsors shown2

Clinical trials

7 shown
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesNCT07843485 · 2026-09-30
RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular DiseaseNCT07843472 · 2026-09-30
RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or ObesityNCT07843498 · 2026-09-30
RECRUITING
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686 · 2026-09-30
NOT_YET_RECRUITING
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsNCT07338214 · 2025-12-17
COMPLETED
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · 2025-04-22
COMPLETED
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539 · 2024-12-09
COMPLETED

Trial status mix

COMPLETED3
RECRUITING3
NOT_YET_RECRUITING1

Phase mix

PHASE23
PHASE33
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.